Procept

PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care in urology. The company's flagship product, the AquaBeam Robotic System, delivers Aquablation therapy, which is the first FDA-cleared surgical robot for the autonomous removal of prostate tissue in men with Benign Prostatic Hyperplasia (BPH). By combining real-time ultrasound imaging with robotic precision and heat-free waterjet ablation, the system aims to provide effective symptom relief while minimizing the side effects associated with traditional surgical methods. The company is headquartered in San Jose, California, and is publicly traded on the NASDAQ under the symbol PRCT.